{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:30:45Z","timestamp":1771104645061,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1245\/s10434-019-07699-9","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T17:03:52Z","timestamp":1565629432000},"page":"561-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis"],"prefix":"10.1245","volume":"27","author":[{"given":"Amanda A. G.","family":"Nijhuis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan D. de A. O.","family":"Santos Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewijka H. J.","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger F.","family":"Uren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omgo E.","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"7699_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599\u2013609.","journal-title":"N Engl J Med"},{"key":"7699_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.sla.0000094440.50547.1d","volume":"238","author":"KA Yao","year":"2003","unstructured":"Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 2003;238:743\u20137.","journal-title":"Ann Surg"},{"issue":"9","key":"7699_CR3","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1245\/s10434-017-5883-6","volume":"24","author":"GM Beasley","year":"2017","unstructured":"Beasley GM, Hu Y, Youngwirth L, et al. Sentinel lymph node biopsy for recurrent melanoma: a multicenter study. Ann Surg Oncol. 2017;24(9):2728\u201333.","journal-title":"Ann Surg Oncol"},{"key":"7699_CR4","first-page":"3197","volume":"34","author":"M Gipponi","year":"2014","unstructured":"Gipponi M, Solari N, Giovinazzo D, et al. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma. Anticancer Res. 2014;34:3197\u2013203.","journal-title":"Anticancer Res"},{"key":"7699_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","volume":"22","author":"RL Read","year":"2015","unstructured":"Read RL, Haydu LE, Saw RPM, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22:475\u201381.","journal-title":"Ann Surg Oncol"},{"key":"7699_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E","volume":"88","author":"XD Dong","year":"2000","unstructured":"Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer. 2000;88:1063\u201371.","journal-title":"Cancer"},{"key":"7699_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1097\/00000478-200309000-00002","volume":"27","author":"L-XL Li","year":"2003","unstructured":"Li L-XL, Scolyer RA, Ka VSK, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence. Am J Surg Pathol. 2003;27:1197\u2013202.","journal-title":"Am J Surg Pathol"},{"key":"7699_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/jso.21770","volume":"104","author":"RF Uren","year":"2011","unstructured":"Uren RF, Howman-Giles R, Chung D, Thompson JF. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma. J Surg Oncol. 2011;104:405\u201319.","journal-title":"J Surg Oncol"},{"key":"7699_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s10434-001-0538-y","volume":"8","author":"OE Nieweg","year":"2001","unstructured":"Nieweg OE, Tanis PJ, Kroon BBR. The definition of a sentinel node. Ann Surg Oncol. 2001;8:538\u201341.","journal-title":"Ann Surg Oncol"},{"key":"7699_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1245\/s10434-018-6689-x","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:993\u20134.","journal-title":"Ann Surg Oncol"},{"key":"7699_CR11","volume-title":"IBM SPSS statistics for windows","author":"IBM Corp","year":"2016","unstructured":"IBM Corp. IBM SPSS statistics for windows. Armonk: IBM Corp.; 2016."},{"key":"7699_CR12","volume-title":"R. A language and environment for statistical computing","author":"R Core Team","year":"2013","unstructured":"R Core Team. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013."},{"key":"7699_CR13","unstructured":"CancerVax Corporation. Vaccine therapy for patients with stage 3 melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00052130 . Accessed 7 May 2019."},{"key":"7699_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejca.2005.10.023","volume":"42","author":"ACJ Van Akkooi","year":"2006","unstructured":"Van Akkooi ACJ, De Wilt JHW, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol: prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer. 2006;42:372\u201380.","journal-title":"Eur J Cancer"},{"key":"7699_CR15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","volume":"242","author":"DL Morton","year":"2005","unstructured":"Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302\u201311.","journal-title":"Ann Surg"},{"key":"7699_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jamcollsurg.2013.12.025","volume":"218","author":"GM Beasley","year":"2014","unstructured":"Beasley GM, Speicher P, Sharma K, et al. Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg. 2014;218:686\u201392.","journal-title":"J Am Coll Surg"},{"issue":"3 Suppl","key":"7699_CR17","doi-asserted-by":"publisher","first-page":"203s","DOI":"10.1245\/ASO.2004.12.918","volume":"11","author":"BJ Coventry","year":"2004","unstructured":"Coventry BJ, Chatterton B, Whitehead F, James C, Gill PG. Sentinel lymph node dissection and lymphatic mapping for local subcutaneous recurrence in melanoma treatment: longer-term follow-up results. Ann Surg Oncol. 2004;11(3 Suppl):203s\u20137s.","journal-title":"Ann Surg Oncol"},{"key":"7699_CR18","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322.","journal-title":"N Engl J Med"},{"key":"7699_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1245\/ASO.2003.01.023","volume":"10","author":"SH Estourgie","year":"2003","unstructured":"Estourgie SH, Nieweg OE, Vald\u00e9s Olmos RA, Hoefnagel CA, Kroon BBR. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol. 2003;10:681\u20138.","journal-title":"Ann Surg Oncol"},{"key":"7699_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jamcollsurg.2016.03.025","volume":"223","author":"AB Gonzalez","year":"2016","unstructured":"Gonzalez AB, Jakub JW, Harmsen WS, Suman VJ, Markovic SN. Status of the regional nodal basin remains highly prognostic in melanoma patients with in-transit disease. J Am Coll Surg. 2016;223:77\u201385.","journal-title":"J Am Coll Surg"},{"key":"7699_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0007-1226(03)00133-4","volume":"56","author":"DJ Dewar","year":"2003","unstructured":"Dewar DJ, Powell BWEM. Sentinel node biopsy in patients with in-transit recurrence of malignant melanoma. Br J Plast Surg. 2003;56:415\u20137.","journal-title":"Br J Plast Surg"},{"key":"7699_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jso.25330","volume":"119","author":"JM Racz","year":"2019","unstructured":"Racz JM, Block MS, Baum CL, Jakub JW. Management of local or regional non-nodal disease. J Surg Oncol. 2019;119:187\u201399.","journal-title":"J Surg Oncol"},{"key":"7699_CR23","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"7699_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"key":"7699_CR25","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u20131801.","journal-title":"N Engl J Med"},{"key":"7699_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757\u201367.","journal-title":"Lancet Oncol"},{"key":"7699_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/jso.21967","volume":"104","author":"HJ Veenstra","year":"2011","unstructured":"Veenstra HJ, Wouters MWJM, Kroon BBR, Vald\u00e9s Olmos RA, Nieweg OE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454\u20137.","journal-title":"J Surg Oncol"},{"key":"7699_CR28","first-page":"12","volume":"127","author":"MM Sakowska","year":"2014","unstructured":"Sakowska MM, Smith N, Coutts RJ. Twelve years\u2019 experience of sentinel lymph node biopsy for melanoma at a rural New Zealand hospital. N Z Med J. 2014;127:12\u201322.","journal-title":"N Z Med J"},{"key":"7699_CR29","doi-asserted-by":"publisher","first-page":"174S","DOI":"10.1245\/ASO.2004.11.912","volume":"11","author":"RA Scolyer","year":"2004","unstructured":"Scolyer RA, Thompson JF, Li L-XL, et al (2004) Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Ann Surg Oncol. 11:174S\u20138S.","journal-title":"Ann Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T13:53:31Z","timestamp":1664114011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07699-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["7699"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07699-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"15 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John F. Thompson has been on advisory boards for and received honoraria from Bristol Meyers Squibb and Merck Sharp Dome. He has been on advisory boards and received honoraria and travel support from Provectus Inc and GlaxoSmithKline.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}